Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-04: CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma
NCT03244306Phase 1Completed
- Sponsor
- Seattle Children's
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in leukemia and lymphoma, sponsored by Seattle Children's. Primary endpoints: Adverse Events at 30 days and Number of successfully and unsuccessfully manufactured and infused CAR T-cell products at 28 days. Started Jul 2017; status: completed.
02
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT03244306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244306.